Lilly Stocks Orforglipron Ahead of FDA Review, Pfizer’s 6.3% Yield GLP-1 Eyes June Data
Eli Lilly has stocked millions of weekly Orforglipron doses before an FDA midyear review, signaling stronger rivalry for Novo Nordisk’s GLP-1 market. Pfizer’s PF-3944 monthly injection, with efficacy readout at the June ADA conference, poses additional competitive pressure despite Pfizer’s 6.3% dividend and looming 2027 drug patents.
1. Orforglipron Inventory Build
Eli Lilly has been amassing inventory of its weekly GLP-1 candidate Orforglipron, reportedly stocking several million capsules ahead of an anticipated FDA decision in mid-2026. The buildup suggests the company aims to ensure immediate market supply if the drug gains approval, intensifying competition in the weight-loss segment.
2. Pfizer PF-3944 Monthly Candidate
Pfizer’s PF-3944 is a monthly GLP-1 injection scheduled for data presentation at the June American Diabetes Association conference. The candidate could differentiate on dosing frequency, while Pfizer’s 6.3% dividend yield may attract investors despite looming patent expirations for several blockbusters in 2027-2028.
3. Competitive Implications for Novo Nordisk
These rival initiatives directly challenge Novo Nordisk’s leading position in GLP-1 therapies. Increased supply readiness by Lilly and potential market entry by Pfizer could intensify price competition and pressure margins for Novo’s obesity and diabetes franchises.